UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (“Orexo”) (STO:ORX) today announced the successful completion of the dose proportionality study for OX219. OX219 is a sublingual formulation of buprenorphine and naloxone, which employs Orexo’s proprietary technologies, and is intended for maintenance treatment of patients suffering from opioid-dependence.
